Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $77.00 price target on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on CAPR. Roth Capital started coverage on shares of Capricor Therapeutics in a research report on Tuesday, May 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.50.

Capricor Therapeutics Trading Down 15.5%

CAPR stock opened at $11.78 on Friday. The firm’s 50-day moving average price is $10.72 and its two-hundred day moving average price is $12.73. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The stock has a market capitalization of $538.08 million, a price-to-earnings ratio of -11.11 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $3.16 million. During the same quarter in the previous year, the firm posted ($0.31) EPS. Equities analysts predict that Capricor Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. raised its stake in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at $68,000. AlphaQuest LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at $78,000. Finally, New York State Common Retirement Fund lifted its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 5,000 shares during the period. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.